Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 

7 Binary Options

US-friendly broker Finpari

 

Enter Stock Symbol:  

Azurrx Biopharma Inc (AZRX)

3.90 +0.32 (+8.94%)

6/23/2017  4:00pm

Open:

3.60

Pre. Close:

3.58

High:

3.90

Low:

3.50

Volume:

44,181

Market Cap:

37.56M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

-

-

Low:

-

-

Close:

-

-

Technical analysis  (as of: 2017-06-23 4:32:23 PM)

Overall:

      

Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.

Target:

Six months: 4.73     One year: 5.53

Support:

Support1: 3.56    Support2: 3.25

Resistance:

Resistance1: 4.05    Resistance2: 4.73

Pivot:

3.68

Moving Averages:

MA(5): 3.64     MA(20): 3.68

MA(100): 3.86     MA(250):

MACD:

MACD(12,26):     Signal(12,26,9): -0.01

%K %D:

%K(14,3): 55.83     %D(3): 45.42

RSI:

RSI(14): 57.29

52-Week:

High: 5.60  Low: 3.25  Change(%): -21.7

Average Vol(K):

3-Month: 25  10-Days 25

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
AZRX has closed below upper band by 17.1%. Bollinger Bands are 14.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 08 Jun 2017 12:00:00 GMT
AzurRx BioPharma Announces Closing of $5.0 Million Private Financing

Mon, 05 Jun 2017 20:26:15 GMT
AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June ...

Mon, 12 Dec 2016 13:02:45 GMT
WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma

Wed, 28 Dec 2016 13:01:56 GMT
AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference

Tue, 06 Dec 2016 13:00:57 GMT
AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN ...

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

NA

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

NA

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  NA

Industry:  NA

Shares Out. (M)

9.63

Shares Float (M)

4.42

% Held by Insiders

% Held by Institutions

Shares Short (K)

11

Shares Short Prior Month (K)

20

Stock Financials

EPS

-1.990

EPS Est. Current Year

-2.950

EPS Est. Next Year

-0.480

EPS Est. Next Quarter

-0.130

Forward EPS

-0.480

Book Value (p.s.)

0.150

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

-85.1

Return on Equity (ttm)

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.754

Qtrly Earnings Growth

Operating Cash Flow (M)

-5.06

Levered Free Cash Flow (M)

-5.87

FoxReading.com

Valuation

P/E

-1.96

P/E Growth Ratio

0.09

P/BV

26.00

P/S

P/CF

-7.42

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.